Post-treatment, treatment-pathway-associated remodeling of the gastric microbiome after chemoradiotherapy-immunotherapy and chemoimmunotherapy: predicted functional axes, external host context, and in silico drug prioritization

Abstract Background Radiotherapy may induce a unique "therapeutic-conditioned" gastric cancer microbiome.We compared two treatment options: chemoradiotherapy combined with immunotherapy (RCI): PGTVp: 30 Gy/12F, PGTVn: 30 Gy/12F + tislelizumab 200 mg + XELOX (oxaliplatin 200 mg, 1 day; capecitabine 1.5 g, once in the morning and evening, for 1–14 days) + PD-1 inhibitor.The control was a chemotherapy immunotherapy (CI) regimen: tislelizumab 200 mg + XELOX (oxaliplatin 200 mg, 1 day; capecitabine 1.5 g, once in the morning and evening, for 1–14 days) + PD-1 inhibitor.We compared microbiome status after RCI and CI, and compared efficacy responses within each treatment pathway. Method A total of 91 post-treatment samples were included (CI, n = 61; RCI, n = 30), stratified by CI-pCR, CI-NR, RCI-pCR, and RCI-NR.We integrated OTU-level Bray-Curtis analysis, CLR-limma classification model, PICRUSt2 prediction, external paired gastric mucosal tissue control set, TCGA-STAD bulk transcriptome, GSE167297 single-cell quality control and annotation, epithelial pseudo-chronology, and GDSC2-targeting compound prioritization. Result We found that there are differences between RCI and CI in Shannon index, Simpson index and community structure.The difference is mainly reflected in the fact that bacterial groups such as Exiguobacterium are higher in RCI (q = 3.42e-02).We found that the four sets of global tests of CI-pCR, CI-NR, RCI-pCR and RCI-NR supported the difference between Shannon (q = 2.43e-02) and Simpson (q = 4.31e-02).We find that the difference in global inspection support is mainly driven by RCI-NR.For the RCI-pCR group, the results showed that the Shannon index was higher (q = 4.56e-02).For the CI group, Lactococcus was related to NR (q = 2.39e-02).Public data show that tumor tissues have higher species richness and diversity, and Exiguobacterium and others overlap in the screened bacterial groups.External single-cell analysis identified marker-inferred immune and stromal cell populations via QC in 23,310/30,365 cells.Pseudochronological analysis provides exploratory epithelial state continuity.Exiguobacterium is a leading candidate strain in the RCI-pCR direction and can be mapped to the predicted SCFA-related fermentation pathway and cell wall/PAMP-related pathway.Host-independent data provide cellular and transcriptome-level context for testing the three-level "biota-function-host" hypothesis. Conclusion Treatment pathways should serve as the primary comparison frame.The acetate/SCFA axis and cell wall/PAMP axis, together with the mTORC2-RhoA-NLRP3 host context, are testable hypotheses rather than proven mechanisms.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11431220/v1
Primary Topic
Gut microbiota and health
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Post-treatment, treatment-pathway-associated remodeling of the gastric microbiome after chemoradiotherapy-immunotherapy and chemoimmunotherapy: predicted functional axes, external host context, and in silico drug prioritization

Minlan Ren, Zhe Wang, Rui Peng, Lingli Huang et al.
Research Square
Gut microbiota and health
preprint

Post-treatment, treatment-pathway-associated remodeling of the gastric microbiome after chemoradiotherapy-immunotherapy and chemoimmunotherapy: predicted functional axes, external host context, and in silico drug prioritization

Minlan Ren, Zhe Wang, Rui Peng, Lingli Huang, Jiayang Gong, Yun Shi, Tingting Li, Gang Li
preprint en

Abstract

Abstract Background Radiotherapy may induce a unique "therapeutic-conditioned" gastric cancer microbiome.We compared two treatment options: chemoradiotherapy combined with immunotherapy (RCI): PGTVp: 30 Gy/12F, PGTVn: 30 Gy/12F + tislelizumab 200 mg + XELOX (oxaliplatin 200 mg, 1 day; capecitabine 1.5 g, once in the morning and evening, for 1–14 days) + PD-1 inhibitor.The control was a chemotherapy immunotherapy (CI) regimen: tislelizumab 200 mg + XELOX (oxaliplatin 200 mg, 1 day; capecitabine 1.5 g, once in the morning and evening, for 1–14 days) + PD-1 inhibitor.We compared microbiome status after RCI and CI, and compared efficacy responses within each treatment pathway. Method A total of 91 post-treatment samples were included (CI, n = 61; RCI, n = 30), stratified by CI-pCR, CI-NR, RCI-pCR, and RCI-NR.We integrated OTU-level Bray-Curtis analysis, CLR-limma classification model, PICRUSt2 prediction, external paired gastric mucosal tissue control set, TCGA-STAD bulk transcriptome, GSE167297 single-cell quality control and annotation, epithelial pseudo-chronology, and GDSC2-targeting compound prioritization. Result We found that there are differences between RCI and CI in Shannon index, Simpson index and community structure.The difference is mainly reflected in the fact that bacterial groups such as Exiguobacterium are higher in RCI (q = 3.42e-02).We found that the four sets of global tests of CI-pCR, CI-NR, RCI-pCR and RCI-NR supported the difference between Shannon (q = 2.43e-02) and Simpson (q = 4.31e-02).We find that the difference in global inspection support is mainly driven by RCI-NR.For the RCI-pCR group, the results showed that the Shannon index was higher (q = 4.56e-02).For the CI group, Lactococcus was related to NR (q = 2.39e-02).Public data show that tumor tissues have higher species richness and diversity, and Exiguobacterium and others overlap in the screened bacterial groups.External single-cell analysis identified marker-inferred immune and stromal cell populations via QC in 23,310/30,365 cells.Pseudochronological analysis provides exploratory epithelial state continuity.Exiguobacterium is a leading candidate strain in the RCI-pCR direction and can be mapped to the predicted SCFA-related fermentation pathway and cell wall/PAMP-related pathway.Host-independent data provide cellular and transcriptome-level context for testing the three-level "biota-function-host" hypothesis. Conclusion Treatment pathways should serve as the primary comparison frame.The acetate/SCFA axis and cell wall/PAMP axis, together with the mTORC2-RhoA-NLRP3 host context, are testable hypotheses rather than proven mechanisms.

Research Square
Jiangsu Cancer Hospital (CN), Second Affiliated Hospital of Nanjing Medical University (CN), Nanjing Medical University (CN)
Government of Jiangsu Province, Jiangsu Cancer Hospital
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon